Personalis (PSNL) has received a United Kingdom Conformity Assessed marking for its NeXT Personal Dx test, the company said Tuesday.
The regulatory milestone allows for clinical use of Personalis' residual disease detection technology in England, Wales, and Scotland, the company said.
The marking confirms that the test meets the UK's safety, health, and performance standards, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.